JPRN-UMIN000054040尚未招募未知
Study on metabolism and bioavailability of newly developed saccharide material, 1-deoxymannose, in humans - Study on metabolism and bioavailability of 1-deoxymannose in humans
akamura Gakuen University0 个研究点目标入组 20 人开始时间: 2024年4月2日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 30years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The exclusion criteria are diabetes mellitus, abnormal glucose metabolism, respiratory disease, chronic gastrointestinal disease (inflammatory bowel disease, irritable bowel syndrome, functional dyspepsia, etc.), abdominal surgery, history of abnormal bowel movements, blood disorders, food allergies, or BMI of 25.0 or higher. Smokers, excessive alcohol drinkers, and pregnant or lactating women will be excluded. Also exclusion criteria are those who regularly consume non-digestible and absorbable carbohydrates, including dietary fiber, and those who routinely consume pharmaceuticals, foods for specified health uses, functional foods, or health foods.
研究者
相似试验
已完成
不适用
Investigation on the bioavailability and metabolism of resveratrol an ingredient of berries in humanshealthy volunteersDRKS00008788Max Rubner-InstitutBundesforschungsinstitut für Ernährung und Lebensmittel107
已完成
不适用
Bioavailability and metabolic effects in humans of n-3 polyunsaturated fatty acids and conjugated linoleic acid after consumption of naturally enriched cow milkutritionNutritional, Metabolic, EndocrineNutritionISRCTN16004121Feiraco Lacteos S.L. (Spain)38
已完成
1 期
To evaluate the efficacy of Odomos Spray & Lotion in twelve Healthy Adult Male Subjects.CTRI/2018/05/014323Dabur India Limited12
已完成
1 期
Bioavailability and tolerability study of two new diclofenac epolamine lecithin gel formulations (2.6% and 3.9%) in comparison with the marketed diclofenac epolamine lecithin gel formulation 1.3% (Effigel® IBSA)ISRCTN80888941IBSA Institut Biochimique S.A12
已完成
1 期
Bioavailability and tolerability study of two new DHEP-medicated plasters in comparison with the marketed DHEP medicated plaster 1.3% (Flector®)DHEP-medicated plasterISRCTN96078237IBSA Institut Biochimique S.A12